Compare Cintas Corporation (CTAS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Sana Biotechnology Inc — how do they compare? Cintas Corporation trades at $202.61 (market cap $79.86B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Cintas Corporation is far larger — about 95.4× Sana Biotechnology Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Sana Biotechnology Inc for 23 Days on average.
| CTAS | SANA | |
|---|---|---|
Market Cap | $79.86B | $836.71M |
Volume | 1,323,583 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $216.53 | $5.92 |
52-Week Low | $163.55 | $2.68 |
Typical Hold Time | 125 Days | 23 Days |
Enterprise Value | $82.33B | $749.96M |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $202.25, up 2.57% today, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals, with price above key moving averages and support at $198. Fundamentally, Q1 2027 revenue reached $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 beating estimates. The company raised fiscal 2027 guidance, signaling confidence in continued organic growth and margin expansion, supported by a robust business model in uniform rental and workplace services.
The outlook remains positive given upward earnings revisions and a consensus price target of $234.60, implying 16% upside. However, risks include elevated valuation multiples (P/E 39.67) and sensitivity to economic cycles affecting corporate spending. Analyst sentiment is mixed with 40% buy ratings, but institutional ownership trends and dividend growth underscore long-term stability. Execution on guidance and margin sustainability are key to maintaining premium valuation.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
